# ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $12,149,398

## Abstract

The Division of Cancer Treatment and Diagnosis, NCI is requesting support for the development and/or use of existing syngeneic model systems for the pre-clinical evaluation and testing of anti-cancer agents in the presence of an intact immune system. This is of particular interest for immuno-oncology (I/O) agents which cannot be evaluated in the standard xenograft model systems requiring the use of immunocompromised animals.

## Key facts

- **NIH application ID:** 10502661
- **Project number:** 75N91019D00024-0-759102100017-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** ETHAN DMITROVSKY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $12,149,398
- **Award type:** —
- **Project period:** 2021-09-16 → 2026-09-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10502661

## Citation

> US National Institutes of Health, RePORTER application 10502661, ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT (75N91019D00024-0-759102100017-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10502661. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*